the effectiveness of the Pfizer shots against infection caused by the Omicron variant fell from 68 percent to just 12 percent in children 5 to 11 years old within one month of being fully vaccinated.
Highlights
- The effectiveness of the Pfizer vaccine for children waned quickly during the Omicron surge in US
- Effectiveness against hospitalisation in children from age 5 to 11 dropped substantially dropped
- Vaccine effectiveness fell more slowly for smaller children as it did for older children
The effectiveness of the Pfizer COVID-19 vaccine for children waned quickly during the Omicron surge in the US, especially among those aged 5 to 11 years, but the preventive was still protective against severe disease, according to a study.
Researchers from the New York State Department of Health and the University at Albany School of Public Health, US, estimated the effectiveness of the Pfizer vaccine against COVID cases and hospitalisations. They used data from 852,384 fully-vaccinated children of 12-17 years of age and 365,502 children aged 5-11 years during December 2021 and January 2022.
The yet-to-be peer-reviewed study, posted on the preprint repository MedRxiv on Monday, found that the effectiveness of the Pfizer shots against infection caused by the Omicron variant fell from 68 percent to just 12 percent in children 5 to 11 years old within one month of being fully vaccinated.
Effectiveness against hospitalisation in the same age group was higher but also dropped substantially, falling from 100 percent in early December to just 48 percent by the end of January.
The study also found that while vaccine effectiveness fell for older children and teens, it fell more slowly than it did for smaller children. The vaccine effectiveness waned from 66 percent in early December to 51 percent by the end of January for children in the age group of 12 to 17, the researchers said. For hospitalisations, vaccine effectiveness fell from 85 percent to 73 percent over the same time frame, they said. "In the Omicron era, the effectiveness against cases of BNT162b2 (Pfizer) declined rapidly for children, particularly those 5-11 years," the authors of the study said.
"However, vaccination of children 5-11 years was protective against severe disease and is recommended," they added. The researchers said these results highlight the potential need to study alternative vaccine dosing for children and the continued importance of layered protections, including mask-wearing, to prevent infection and transmission.
ALSO READ | Canada authorises first plant-based COVID-19 vaccine
ALSO READ | All Covid legal restrictions come to an end in England
ALSO READ | India reports 6,915 new COVID cases, 180 deaths in last 24 hours
ALSO READ | Delhi reports 258 fresh Covid cases today, 47% lower than yesterday
